Mounjaro and a History of Pancreatitis: What the Evidence Says

What the MHRA's January 2026 safety update means for people with pancreatic history

On 29 January 2026, the MHRA published a Drug Safety Update covering all GLP-1 receptor agonist medicines, including tirzepatide. The update made explicit what had been signalled in earlier product literature: acute pancreatitis is a recognised, if infrequent, adverse effect of this class of medicines. Clinicians were reminded to counsel patients about the symptoms and to discontinue treatment if pancreatitis is suspected.

For someone who has never had pancreatitis, this risk sits in the background of their prescriber's thinking. For someone who has had it (whether a single acute episode, a recurrent pattern, or chronic pancreatitis) it moves to the foreground. The reason is straightforward: a pancreas that has already been inflamed may carry a different risk profile than one that has not. The Mounjaro SmPC does not list previous pancreatitis as an absolute contraindication in all circumstances, but it does require the prescriber to evaluate it on an individual basis. That distinction matters, because it means some people in this situation may still be suitable for treatment. The decision is never made by default, it is made by a clinician looking at your specific history, the cause of your previous episode, how long ago it was, and whether any underlying trigger (such as gallstones or high triglycerides) has since been addressed. Our page looking at how Mounjaro and pancreatitis interact goes into that clinical background in more detail.

The NHS medicines page for tirzepatide also flags pancreatitis as a condition to discuss with a prescriber before starting. If your history includes pancreatitis, disclosing it fully in your consultation is not optional, it is the information a prescriber needs to protect you.

When pancreatitis symptoms on treatment need urgent attention

Whether or not you have a prior history, understanding what pancreatitis feels like is important for anyone taking Mounjaro. The cardinal symptom is severe, persistent abdominal pain (typically centred in the upper stomach) that spreads through to the back. It often comes alongside nausea or vomiting and does not ease with rest or ordinary painkillers. That combination, on a GLP-1 medicine, should prompt an immediate call to 111 or a visit to A&E. It is not a symptom to write off as ordinary nausea from the injection.

Ordinary GLP-1 side effects (queasiness after a dose increase, loose stools during the first few weeks, or mild bloating) are different in character. They tend to appear shortly after a dose step, they are manageable, and they generally improve as the body adjusts. Pancreatitis pain does not have that pattern. It is disproportionate, persistent and often radiates. You will find a fuller breakdown of where everyday gut effects end and something requiring assessment begins on our Mounjaro side effects page.

For people with a documented history of pancreatitis who are approved for treatment after clinical review, this symptom awareness matters even more. Carry that mental checklist (the back pain specifically, the severity, the persistence) in the same way you might keep your pen in the fridge door at a consistent spot: routine awareness, not anxiety.

What a prescriber considers before approving treatment in someone with this history

A responsible prescriber will not simply cross-reference a contraindication list. They will want to understand the cause of your previous pancreatitis. Gallstone-related episodes, alcohol-related episodes and idiopathic episodes each carry different implications for ongoing risk, and some causes can be fully resolved. Chronic pancreatitis with ongoing exocrine insufficiency is a different clinical picture from a single acute episode five years ago with no recurrence. Those details change the risk calculus substantially.

They will also look at other factors: current triglyceride levels (very high triglycerides are themselves a pancreatitis risk factor and a reason GLP-1 prescribers stay alert), current medications, and whether you have any gallbladder disease, since GLP-1 medicines are associated with an increased risk of gallbladder events. If you are also weighing up whether you can take Mounjaro with a history of pancreatitis, that page works through the key factors a prescriber will consider. A more detailed look at how that pancreatic risk sits within the broader evidence base is available on our page covering the risk of pancreatitis with Mounjaro.

If, after reviewing all of this, a prescriber considers treatment reasonable, they may also set specific monitoring expectations or explain which symptoms should prompt you to pause and seek advice immediately. Treatment is then reviewed before every repeat, not set and forgotten. Our clinical team follows that standard on every order.

When the answer is likely to be 'not suitable', and what to do then

There are circumstances where a prescriber will conclude that Mounjaro is not appropriate, even after a thorough review. Active pancreatitis, chronic pancreatitis that remains symptomatic, or a recent acute episode with an unresolved trigger are situations where the risk of re-inflammation is considered too high. That is a careful clinical judgement, not a bureaucratic rule. If you want to understand the evidence behind that judgement, our page examining whether Mounjaro can cause pancreatitis sets out what the data currently shows.

If you fall into that category, it is worth understanding that other licensed weight-management options exist. Our weight-loss treatment overview sets out what is available in the UK and how each option differs. A prescriber can discuss which, if any, might suit your particular health picture. The cost of private treatment is covered separately on our Mounjaro cost page, so you have the full picture if treatment does turn out to be suitable for you.

If you are unsure about your own situation, the right next step is a consultation with a qualified prescriber. Our prescribers discuss suitability and safety, including prior medical history, as part of every consultation, you can start a free consultation here. Nothing about the outcome is pre-decided; it is a proper clinical conversation.